- Home
- OB vs MOLN Comparison
OB vs MOLN Comparison
Compare OB & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OB
- MOLN
- Stock Information
- Founded
- OB 2006
- MOLN 2004
- Country
- OB United States
- MOLN Switzerland
- Employees
- OB N/A
- MOLN N/A
- Industry
- OB Industrial Machinery/Components
- MOLN
- Sector
- OB Industrials
- MOLN
- Exchange
- OB Nasdaq
- MOLN Nasdaq
- Market Cap
- OB 219.5M
- MOLN 218.1M
- IPO Year
- OB 2021
- MOLN 2021
- Fundamental
- Price
- OB $5.10
- MOLN $5.42
- Analyst Decision
- OB Buy
- MOLN Hold
- Analyst Count
- OB 5
- MOLN 1
- Target Price
- OB $5.50
- MOLN $4.50
- AVG Volume (30 Days)
- OB 116.7K
- MOLN 17.4K
- Earning Date
- OB 11-07-2024
- MOLN 08-26-2024
- Dividend Yield
- OB N/A
- MOLN N/A
- EPS Growth
- OB N/A
- MOLN N/A
- EPS
- OB N/A
- MOLN N/A
- Revenue
- OB $903,518,000.00
- MOLN $7,105,397.00
- Revenue This Year
- OB $1.24
- MOLN N/A
- Revenue Next Year
- OB $7.66
- MOLN $29.41
- P/E Ratio
- OB N/A
- MOLN N/A
- Revenue Growth
- OB N/A
- MOLN N/A
- 52 Week Low
- OB $3.42
- MOLN $3.32
- 52 Week High
- OB $5.48
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- OB 60.54
- MOLN 47.39
- Support Level
- OB $4.91
- MOLN $5.11
- Resistance Level
- OB $5.48
- MOLN $6.15
- Average True Range (ATR)
- OB 0.20
- MOLN 0.39
- MACD
- OB 0.03
- MOLN -0.09
- Stochastic Oscillator
- OB 69.60
- MOLN 27.43
About OB Outbrain Inc.
Outbrain Inc is a platform powering the open web that matches audiences with personalized content and ads, driving quality engagement. Its platform delivers ads to end-users that appear as links to articles, products, and videos on media partners' sites. It derives revenue from advertisers through user engagement with the ads that it places on media partners' web pages and mobile applications. The company has its geographic presence in Europe, the Middle East, and Africa followed by the USA and others.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.